Discovery of wedelolactone from Eclipta Prostrata (L.) Linn. as a natural PDE4 inhibitor with potent anti-psoriasis effects

Abstract

Psoriasis is a chronic inflammatory disorder for which phosphodiesterase-4 (PDE4) inhibitors have emerged as promising therapeutic agents due to an ability to regulate inflammatory signaling pathways. In this study 1200 methanolic extracts from Chinese medicinal plants were screened and Eclipta prostrata (L.) Linn. ( E. prostrata) was shown to have potent PDE4 inhibitory activity. Bioassay-guided fractionation further demonstrated that the ethyl acetate (EA) fraction exhibited the highest inhibitory activity, leading to the isolation of wedelolactone (WDL) as the principal bioactive compound (IC₅₀ = 2.8 μM). Molecular dynamics simulations revealed that WDL forms stable interactions with PDE4D through hydrogen bonding and hydrophobic contacts. E. prostrata-EA and WDL significantly suppressed pro-inflammatory cytokines in keratinocytes in vitro. Topical application of WDL demonstrated superior anti-psoriatic efficacy compared to calcipotriol in vivo, as evidenced by reduced Psoriasis Area and Severity Index scores, normalized epidermal thickness, and improved inflammatory cytokine profiles. WDL exhibited favorable metabolic stability in liver microsomes and demonstrated a good safety profile in subacute toxicity assessments with no systemic toxicity. These findings established WDL as a potent and safe topical PDE4 inhibitor, highlighting the potential of WDL as a novel therapeutic candidate for psoriasis and warranting further clinical development.

Keywords

Eclipta prostrata (L.) Linn. / Wedelolactone / Phosphodiesterase-4 inhibitor / Psoriasis / Molecular dynamics simulation

References

[1] Lowes MA, Suarez-Farinas M, Krueger JG: Immunology of Psoriasis. Annual Review of Immunology 2014, 32: 227-255.

[2] Boehncke WH, Schn MP: Psoriasis. The Lancet 2015, 386: 983-994.

[3] Ding X, Wang T, Shen Y, Wang X, Zhou C, Tian S, et al.: Prevalence of Psoriasis in China: A Population-based Study in Six Cities. European Journal of Dermatology 2012, 22: 663-667.

[4] Menter A, Korman NJ, Elmets CA, Feldman SR, Gelfand JM, Gordon KB, et al.: Guidelines of Care for the Management of Psoriasis and Psoriatic Arthritis: Section 4. Guidelines of Care for the Management and Treatment of Psoriasis with Traditional Systemic Agents. Journal of the American Academy of Dermatology 2009, 61: 451-485.

[5] Samarasekera E, Sawyer L, Wonderling D, Tucker R, Smith C: Topical Therapies for the Treatment of Plaque Psoriasis: Systematic Review and Network Meta-analyses. British Journal of Dermatology 2013, 168: 954-967.

[6] Warren RB, Griffiths CE: Systemic Therapies for Psoriasis: Methotrexate, Retinoids, and Cyclosporine. Clinics in Dermatology 2008, 26: 438-447.

[7] Reich K, Thaci D, Mrowietz U, Kamps A, Neureither M, Luger T: Efficacy and Safety of fumaric Acid Esters in the Long-term Treatment of Psoriasis - A Retrospective Study (FUTURE). Journal Der Deutschen Dermatologischen Gesellschaft 2009, 7: 603-611.

[8] Menter A, Strober BE, Kaplan DH, Kivelevitch D, Prater EF, Stoff B, et al.: Joint AAD-NPF Guidelines of Care for the Management and Treatment of Psoriasis with Biologics. Journal of the American Academy of Dermatology 2019, 80: 1029-1072.

[9] Warren RB, Smith CH, Yiu ZZN, Ashcroft DM, Barker J, Burden AD, et al.: Differential Drug Survival of Biologic Therapies for the Treatment of Psoriasis: A Prospective Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). Journal of Investigative Dermatology 2015, 135: 2632-2640.

[10] Bhosle MJ, Kulkarni A, Feldman SR, Balkrishnan R: Quality of Life in Patients with Psoriasis. Health and Quality of Life Outcomes 2006, 4: 35.

[11] Ekor M: The Growing Use of Herbal Medicines: Issues Relating to Adverse Reactions and Challenges in Monitoring Safety. Frontiers in Pharmacology 2014, 4: 177.

[12] Tanghetti E, Lebwohl M, Stein Gold L: Tazarotene Revisited: Safety and Efficacy in Plaque Psoriasis and Its Emerging Role in Treatment Strategy. Journal of Drugs in Dermatology 2018, 17: 1280-1287.

[13] Lin TK, Zhong LL, Santiago JL: Anti-Inflammatory and Skin Barrier Repair Effects of Topical Application of Some Plant Oils. International Journal of Molecular Sciences 2017, 19: 70.

[14] Auh JH, Madhavan J: Protective Effect of a Mixture of Marigold and Rosemary Extracts on UV-induced Photoaging in Mice. Biomedicine & Pharmacotherapy 2021, 135: 111178.

[15] Zhang Q, Sun L, Wu L, Wang X, Chen L, Chen Y, et al.: Platycladus orientalis (L.) Franco Demonstrates Effective Anti-psoriasis Effects by Inhibiting PDE4 with Favorable Safety Profiles . Chinese Chemical Letters 2024: 110795.

[16] Houslay MD, Schafer P, Zhang KYJ: Keynote Review: Phosphodiesterase-4 as a Therapeutic Target. Drug Discovery Today 2005, 10: 1503-1519.

[17] Li BB, He SC, Liu R, Huang LL, Liu G, Wang RX, et al.: Total Glucosides of Paeony Attenuates Animal Psoriasis Induced Inflammatory Response through Inhibiting STAT1 and STAT3 Phosphorylation. Journal of Ethnopharmacology 2019, 243: 112121.

[18] Serezani CH, Ballinger MN, Aronoff DM, Peters-Golden M: Cyclic AMP: Master Regulator of Innate Immune Cell Function. American Journal of Respiratory Cell and Molecular Biology 2008, 39: 127-132.

[19] Schafer PH, Parton A, Capone L, Cedzik D, Brady H, Evans JF, et al.: Apremilast is a Selective PDE4 Inhibitor with Regulatory Effects on Innate Immunity. Cellular Signalling 2014, 26: 2016-2029.

[20] Torres T, Puig L: Apremilast: A Novel Oral Treatment for Psoriasis and Psoriatic Arthritis. American Journal of Clinical Dermatology 2018, 19: 23-32.

[21] Keating GM: Apremilast: A Review in Psoriasis and Psoriatic Arthritis. Drugs 2017, 77: 459-472.

[22] Papp K, Reich K, Leonardi CL, Kircik L, Chimenti S, Langley RG, et al.: Apremilast, an Oral Phosphodiesterase 4 (PDE4) Inhibitor, in Patients with Moderate to Severe Plaque Psoriasis: Results of a Phase III, Randomized, Controlled Trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1). Journal of the American Academy of Dermatology 2015, 73: 37-49.

[23] Feng L, Zhai YY, Xu J, Yao WF, Cao YD, Cheng FF, et al.: A Review on Traditional Uses, Phytochemistry and Pharmacology of Eclipta prostrata (L.) L. Journal of Ethnopharmacology 2019, 245: 112109.

[24] Saleem M, Nazir M, Ali MS, Hussain H, Lee YS, Riaz N, et al.: Antimicrobial Natural Products: an Update on Future Antibiotic Drug Candidates. Natural Product Reports 2010, 27: 238-254.

[25] Wagner H, Geyer B, Kiso Y, Hikino H, Rao GS: Coumestans as the Main Active Principles of the Liver Drugs Eclipta alba and Wedelia calendulacea. Planta Medica 1986, 52: 370-374.

[26] Susantha Priyadarshani M, Gajavinduge Harsha M, Rathnayaka, Mudiyanselage Madusha J, Sujatha Pushpakanthi H: Pharmacological Activities of Eclipta alba (L.) Hassk. (Bhringaraja): A Review. GSC Advanced Research and Reviews 2023, 15: 085-097.

[27] Card GL, England BP, Suzuki Y, Fong D, Powell B, Lee B, et al.: Structural Basis for the Activity of Drugs that Inhibit Phosphodiesterases. Structure 2004, 12: 2233-2247.

[28] Li Z, Cai YH, Cheng YK, Lu X, Shao YX, Li X, et al.: Identification of Novel Phosphodiesterase-4D Inhibitors Prescreened by Molecular Dynamics-Augmented Modeling and Validated by Bioassay. Journal of Chemical Information and Modeling 2013, 53: 972-981.

[29] Oh KJ, Deng Y: An efficient parallel implementation of the smooth particle mesh Ewald method for molecular dynamics simulations. Computer Physics Communications 2007, 177: 426-431.

[30] Yu SJ, Yu JH, Yu ZP, Yan X, Zhang JS, Sun JY, et al.: Bioactive Terpenoid Constituents from Eclipta prostrata. Phytochemistry 2020, 170: 112192.

[31] 吴疆, 侯文彬, 张铁军, 韩英梅 : 墨旱莲的化学成分研究. 中草药 2008, 39: 814-816.

[32] Zhang JS, Guo QM: Studies on the Chemical Constituents of Eclipta prostrata (L) . Yao xue xue bao = Acta pharmaceutica Sinica 2001, 36: 34-37.

[33] Zafar A, Singh S, Naseem I: Cytotoxic Activity of Soy Phytoestrogen Coumestrol against Human Breast Cancer MCF-7 Cells: Insights into the Molecular Mechanism. Food and Chemical Toxicology: an International Journal Published for the British Industrial Biological Research Association 2017, 99: 149-161.

[34] Tao S, Liang XY, Wang Y, Wang Y: Screening of Active Compounds with Myocardial Protective Effects from Tongmai Yangxin Pill. Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical Sciences 2015, 44: 145-153.

[35] Sun H, Ma Z, Lu D, Wu B: Regio-and Isoform-specific Glucuronidation of Psoralidin: Evaluation of 3-o-glucuronidation as a Functional Marker for UGT1A9. Journal of Pharmaceutical Sciences 2015, 104: 2369-2377.

[36] Khan AN, Perveen S, Malik A, Afza N, Iqbal L, Latif M, et al.: Conferin, Potent Antioxidant and Anti-inflammatory Isoflavone from Caragana conferta Benth. Journal of Enzyme Inhibition and Medicinal Chemistry 2010, 25: 440-444.